Hikma Pharmaceuticals
Tracked across 1 events · 7 articles · First seen Jun 04, 2026 · Last active Aug 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The U.S. Supreme Court ruled in favor of Hikma Pharmaceuticals>>>, affirming its right to sell a generic version of Vascepa using a 'skinny label' without infringing on Amarin Corporation>>>'s patents. This decision reduces Hikma Pharmaceuticals>>>'s vulnerability to patent lawsuits and supports its business model of providing lower-cost generic drugs.
Jun 04, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Hikma Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard